
Opinion|Videos|April 25, 2025
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Author(s)Alexandra K. Golant, MD
Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- Beyond efficacy and safety, what other factors—such as cost, insurance coverage, or caregiver education—will determine how widely ruxolitinib cream is adopted in pediatric dermatology, specifically in younger children?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
2
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
3
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
4
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
5

















